REG - HealthBeacon PLC HealthBeacon - HBCN - Directorate Change and Committee Update

London Stock ExchangeAnnouncement

26/04/2022 08:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220426:nRSZ2562Ja&default-theme=true

RNS Number : 2562J  HealthBeacon PLC  26 April 2022

26 April 2022

HealthBeacon plc

Appointment of Director

 

HealthBeacon plc ("HealthBeacon" or the "Company"), the leading digital
therapeutics company developing products for managing injectable medications
for patients in the home, is pleased to announce the appointment of Ms Orla
O'Gorman as Non-Executive Director of the Company with immediate effect. Upon
her appointment, Ms O'Gorman will join the Audit & Risk Committee and the
Nomination Committee.

Orla O'Gorman, is a Fellow of the Chartered Accountants of Ireland, has over
25 years' experience as an executive leader and adviser to a range of
businesses. Orla spent seven years at the Irish Stock Exchange ("ISE"), where
she was Head of Equity. She was centrally involved in the sale of the ISE to
Euronext in 2018 and, following that transaction, was appointed as Head of
Listing for UK and Ireland. Prior to joining the ISE, Ms O'Gorman founded OR
Associates, and previously held senior management positions at Eurologic
Systems, ABN AMRO and PwC.

Ms O'Gorman is a non-executive director of Cairn Homes plc and Elite SpA. Orla
is a member of the European Commission's SME Technical Expert Group, Chartered
Accountants Ireland Sustainability Expert Working Group and the Advisory Board
of Elkstone Ventures. Orla is a qualified accountant, holds a Bachelor of
Commerce from University College Dublin and a Master of Accounting from UCD
Smurfit School.

Robert Garber, Chairman commented on the appointment:

"We are delighted to announce the appointment of Orla to HealthBeacon's board.
This appointment comes at a pivotal time for our business, following our
listing in December 2021 and key developments in early 2022.

Orla has an exceptional track record and brings significant capital markets
experience to the Board. Orla's Environment and Governance knowledge,
experience and insight will further support both of these core themes across
HealthBeacon. We look forward to working with Orla as the Company continues to
grow on its path to becoming the world's leading digital therapeutics platform
for injectable medications."

 

Committee Composition

Following the appointments of Orla O'Gorman to the Board, the below table
reflects the new composition of each Committee.

 

 Audit & Risk           Remuneration              Nomination           Disclosure
 Orla O'Gorman (Chair)  Rebecca Shanahan (Chair)  Mary Harney (Chair)  Orla O'Gorman (Chair)
 Mary Harney            Robert Garber             Robert Garber        Jim Joyce
 Rebecca Shanahan       Mary Harney               Rebecca Shanahan     Laurence Flavin

 

 Enquiries:
 HealthBeacon:                                    Investor.Relations@HealthBeacon.com

 Laurence Flavin

 Goodbody (Euronext Listing Sponsor and Broker):  +353 (1) 667 0420

 David Kearney
 Stephen Kane

 Drury (Public Relations):
 Billy Murphy                                     +353 (0) 87 231 3085
 Cathal Barry                                     +353 (0) 87 227 9281

 

About HealthBeacon

Headquartered in Dublin, HealthBeacon is an Irish digital therapeutics company
that develops products for managing injectable medications for patients in the
home. The HealthBeacon Injection Care Management System tracks adherence and
persistence with medication schedules through the provision of medication
management reminders, safe and sustainable sharps disposal devices,
educational tools, and artificial intelligence (AI) driven data analytics. The
Company operates in 17 countries primarily across Europe, North America and
the United Kingdom employs more than 60 people and has obtained more than 30
design and utility patents. Peer reviewed evidence supports a 19% improvement
in therapy persistence by patients and a 26% improvement in adherence to
therapy, which improves clinical outcomes and significantly improves
efficiency in health systems. The Company's mission is to become the world's
leading digital therapeutics platform for injectable medications.

 

Ends

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  ISEZELFLLZLEBBZ